Tetherex Pharmaceuticals Stock

tetherex.comHealthcareFounded: 2002Funding to Date: $68.65MM

Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).

Register for Details

For more details on financing and valuation for Tetherex Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Tetherex Pharmaceuticals.

Register Today

Team

Management Team

Ziad Kawar Ph.D
Senior Scientist
Jonathan Stocker Ph.D
Senior Director, Clinical Development
Russell Rother Ph.D
President, Board Member & Chief Operating Officer
Richard Alvarez
Vice President, Operations & Research
Scott Rollins Ph.D
Chief Executive Officer, Co-Founder & Chairman
Richard Cummings Ph.D
Co-Founder
David Falconer
Vice President, Quality and Program Management

Board Members

Philip Jones MD
Scott Rollins Ph.D
Rodger McEver MD
Todd Foley
MPM Capital
David Keiser

Other companies like Tetherex Pharmaceuticals in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector